Zydus Lifesciences Reports Strong Q4 and Full Year FY26 Results; Approves Dividend and Buyback

Zydus Lifesciences Reports Strong Q4 and Full Year FY26 Results; Approves Dividend and Buyback​

Zydus Lifesciences Limited announced its financial results for the fourth quarter (Q4) and the full fiscal year (FY) 2026, showing significant year-over-year growth across key operational areas. The company also recommended a 100% dividend for FY 2025-26 and approved a buyback of equity shares.

Consolidated Financial Performance​

The company reported robust revenue growth and strong profitability metrics for the quarter and the full year.

For the quarter ended March 31, 2026, the highlights include:


Consolidated figures for the full fiscal year 2026 compared to FY 2025 were:


The company reported that Net Debt to Equity ratio as of March 31, 2026, stood at 0.16x, while Net Debt to EBITDA was 0.50x at the end of March 2026.

Key Business Segments Showcase Growth​

The company noted strong performance across several key business segments during Q4 FY26 and the full year FY26.

Pharma Business:
The Pharma Business recorded revenues of Rs. 56,436 mn in Q4 FY26, up 4.9% year-over-year (YoY), and represented 24% of the consolidated revenues for the quarter.

• India Formulations: Registered revenues of Rs. 17,528 mn, showing a 14.0% YoY increase. The segment reported that the Chronic segment continues to grow quickly, driving overall business expansion. The company launched Tishtha TM, the world's first biosimilar of Nivolumab, and Anyra TM, the country's first indigenously developed biosimilar of Aflibercept 2 mg.
• Consumer Wellness: Reported revenues of Rs. 14,633 mn in Q4 FY26, marking a 61.1% YoY increase. The international business, including the Comfort Click business, achieved 31.4% growth on a like-to-like basis.
• North America Formulations: Registered revenues of Rs. 29,523 mn, a 5.3% quarter-over-quarter (QoQ) increase, though down 5.7% YoY. In the US generics space, the business filed 3 ANDAs and received approval for 9 ANDAs during the quarter.
• IM Formulations: Posted revenues of Rs. 8,041 mn in Q4 FY26, demonstrating a 45.0% YoY growth.

MedTech Business:
This segment reported registered revenues of Rs. 3,275 mn in Q4 FY26, contributing 4% to the consolidated revenues. The business filed 2 new product dossiers via the 505(b)(2) route on the US specialty front and launched Zycubo ® for ultra-rare Menkes disease in the US.

APIs:
The API business generated revenues of Rs. 1,219 mn in Q4 FY26, which accounted for 2% of consolidated revenues.

Strategic and Innovation Updates​

On the strategic front, Zydus Lifesciences confirmed its dedication to future growth through its pipeline.

• Research & Development (R&D): The company advanced its innovative pipeline by initiating Phase III clinical trials for a second biosimilar antibody drug conjugate in India. Furthermore, it successfully completed the clinical development of an in-licensed Pembrolizumab biosimilar candidate FYB206 for the US market.
• International Partnerships: Zydus entered into a definitive agreement to acquire Assertio Holdings, Inc., a US-based pharmaceutical company, for a consideration of US$ 166 mn, aimed at strengthening its specialty footprint in the US market.
• Clinical Development: The company secured Orphan Drug Designation (ODD) status from the USFDA for Desidustat for the treatment of sickle cell disease and received approval from DCGI to conduct two Phase III clinical trials in India for Zintrodiazine.

Investor Actions​

Following the announcement, the company disclosed board recommendations for shareholder actions:

• The Board recommended a dividend of 100% for FY 2025-26.
• The Board approved the buyback of equity shares for an aggregate amount up to Rs. 11,000 mn, priced at Rs. 1,150 per share.

ZYDUSLIFE Stock Price Movement​

Today, Zydus Lifesciences Limited shares rallied, gaining 2.68% to settle at ₹1017.7. The stock's strong performance was supported by significant market interest, with trading volume reaching 5.88 million shares.